Trifluridine/tipiracil (FTD/TPI) in advanced gastric cancer-a retrospective cohort study providing real-world survival and safety data from the United Kingdom.

ABSTRACT:

Background

In advanced gastric adenocarcinoma (aGC), the TAGS study demonstrated a survival advantage of trifluridine/tipiracil (FTD/TPI) over placebo in ≥3^rd line setting. This led to approval in the United Kingdom (UK). Clinical trial and real-world patients often differ in age, fitness and comorbidity, which has implications for safety and survival. Real-world data can inform clinical practice. This study sought to define the UK patient population who have received FTD/TPI and compare outcomes to TAGS.

Methods

This was a retrospective study. Patients with aGC commenced on FTD/TPI prior to 1^st February 2024 were eligible. Patients were identified from electronic health records. Data on baseline demographics and cancer outcome, including survival and t

SUBMITTER: Salf J 

PROVIDER: S-EPMC12780684 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature